Did Vitamin D, Omega-3 and Exercise Lower Cancer Risk? A Post Fact-Checked

The claim, and the verdict

An Instagram post from @gaingoat describes "a three-year randomized trial across five European countries" that tested daily vitamin D3 (2,000 IU), omega-3 (1 g) and a simple home strength program in adults 70 and older. It says "1.5% of the combined group developed invasive cancer compared with 4.4% on placebo, meaning one cancer was prevented for every 35 people over three years."

Verdict: mostly accurate, but it needs context. The counts and estimates match the published paper. The post also says, fairly, that cancer was an exploratory outcome and that larger trials are needed. What a quick read can miss is how few cancers sit behind the headline and how far this is from advice to change what you take.

What the paper actually reports

The post cites a 2022 paper in Frontiers in Aging by Bischoff-Ferrari and colleagues, from the DO-HEALTH trial.

• Who: 2,157 generally healthy adults aged 70 or older living in the community, with a mean age of 74.9 years.
• Design: a three-year randomized trial in five European countries. People were assigned to vitamin D3, omega-3, home exercise, or placebo, alone and in every combination.
• Doses: 2,000 IU a day of vitamin D3 and 1 g a day of marine omega-3s, plus a simple home strength exercise program.
• Cancers: 81 participants developed invasive cancer during follow-up.

Checking the numbers

• 1.5% versus 4.4%: consistent with the paper's counts, but not stated in it. The paper reports 4 versus 12 cancer cases for all three treatments combined versus placebo (a hazard ratio of 0.39, 95% CI 0.18 to 0.85), and the group sizes are 264 and 270. Dividing gives 1.5% and 4.4%, which is what the post shows. The paper's own summary measures are the hazard ratio and a number needed to treat, not these percentages.
• "One cancer prevented for every 35 people": correct as the paper's estimate. The paper gives a number needed to treat of 35 at three years, but with a wide range (95% CI, 26 to 137). It calculated this from Kaplan-Meier curves, not from the simple percentages above.
• "Held when people with a history of cancer were excluded": correct. The paper's sensitivity analysis excluded 185 participants with a reported history of cancer and gave a hazard ratio of 0.35 (0.15 to 0.80), based on 2 versus 11 cases.
• "Exploratory outcome with 81 cases": correct. The paper calls any new invasive cancer a "pre-defined exploratory outcome."
• "Already healthy and physically active": the paper says 82.6% were physically active at the start and the group was "largely vitamin D-replete." The post's "most had adequate vitamin D levels" fits: about 41% were below 20 ng/ml.

What the post does not tell you

The headline compares two small groups. The trial had eight groups. The 1.5% versus 4.4% comparison uses only two of them, with 16 cancers between them. With so few events, chance can move the result a lot.

The single treatments did not clearly work. For vitamin D3 alone, the hazard ratio was 0.76 (0.49 to 1.18). For omega-3 alone it was 0.70 (0.44 to 1.09). For home exercise alone it was 0.74 (0.48 to 1.15). Each interval includes 1.0, meaning no effect cannot be ruled out. Some two-treatment combinations came closer: omega-3 plus home exercise had a hazard ratio of 0.52 (0.28 to 0.97; 12 versus 26 cases). The paper describes a cumulative benefit when all three were combined, with a hazard ratio of 0.39 (0.18 to 0.85).

Cancer was not what the trial was built to test. The paper says the trial was designed to support healthy aging with other primary outcomes. It also says the trial "may be considered small for a cancer endpoint trial" and that "for cancer prevention, the duration of our trial would be considered short."

Many comparisons were made. When researchers look at many groups and outcomes, some striking results appear by chance. The authors themselves write that their results are "based on multiple comparisons and requiring replication."

The group was specific. These were healthy, mostly active, mostly vitamin D-replete adults aged 70 and up. The result may not apply to younger people, to people who are less active or unwell, or to people with cancer.

Funding. The paper lists a European Commission grant plus support from the University of Zurich and several companies (DNP, Roche, NESTEC, Pfizer and Streuli). It states that the funders had no role in the design, analysis or publication. Funding is not evidence of bias, but it is worth knowing.

What NCI says about the bigger picture

We searched PubMed for later DO-HEALTH cancer-incidence reports and found none; the DO-HEALTH papers since then that we saw looked at other outcomes (for example, physical function in people who developed cancer), and we did not read them. A related trial, VITAL, also tested vitamin D and omega-3. NCI's vitamin D page states: "After 5 years of follow-up, the vitamin D/omega-3 group had the same overall cancer incidence as the placebo group." It adds: "Most randomized controlled trials have found that vitamin D supplements, with or without calcium, do not reduce the risk of developing cancer overall or of developing specific cancers."

That does not cancel out DO-HEALTH. The trials had different people, doses and designs. It does mean that one exploratory finding sits beside other randomized trials that mostly did not see a cancer benefit.

What this does not mean

• It does not show that vitamin D, omega-3 or exercise prevents cancer. The authors called it a possible benefit that needs confirmation.
• It does not mean any one of the three works alone. Alone, none showed a clear effect.
• It does not tell anyone to start or stop a supplement. Doses, other medicines and health conditions matter, so questions about supplements belong with your care team or pharmacist.
• It does not mean exercise is pointless. Physical activity has other well-documented health benefits. See how much exercise lowers cancer risk.
• It does not mean the post is dishonest. It reports the numbers correctly and names the study's limits. It is short on the context above.

A calm takeaway

Good science often starts with a promising exploratory result. Confirming it takes a larger trial designed to test cancer from the start, with more cases and longer follow-up. Until then, the fair reading is "interesting, unproven."

Sources

• https://www.instagram.com/p/Dd0AaEAFmpx/
• https://www.frontiersin.org/articles/10.3389/fragi.2022.852643/full
• https://www.cancer.gov/about-cancer/causes-prevention/risk/diet/vitamin-d-fact-sheet

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.